Avalon GloboCare to Present at Biotech Showcase™ 2020
January 06 2020 - 8:30AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, today
announced its Chief Executive Officer, Dr. David Jin, will present
at the Biotech Showcase™ 2020 conference being held January 13-15,
2020 at the Hilton San Francisco Union Square in San Francisco,
California.
Details of the presentation are as follows:
Event:
Biotech Showcase™ 2020
Date:
Monday, January 13, 2020
Time:
11:00 a.m. (PST)
Track:
Yosemite C (Ballroom Level)
Location: Hilton
San Francisco Union Square
Avalon will also host one-on-one meetings with investors and
industry stakeholders during the event. Registered Biotech
Showcase™ 2020 attendees may request one-on-one meetings with
Avalon through the online partneringONE® system or by emailing
avco@crescendo-ir.com.
Biotech Showcase™ is one of the industry's largest annual
healthcare investor and partnering conferences, bringing together
biopharmaceutical and life sciences company executives, investors,
sector analysts, bankers and industry stakeholders. More than 400
presentations from mid-, small- and micro-cap public and private
companies are expected to present at the event. Qualified investors
and buy- and sell-side analysts are invited to request a
complimentary registration to attend Biotech Showcase™ and its
sister event, Digital Medicine & Medtech Showcase. For more
information please visit:
https://informaconnect.com/biotech-showcase/.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative exosome technologies and
cellular therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth,
development, as well as competitiveness in healthcare and CellTech
industry markets. Through its subsidiary structure with unique
integration of verticals from innovative R&D to automated
bioproduction and accelerated clinical development, Avalon is
establishing a leading role in the fields of in vitro diagnostics
(''liquid biopsy''), immune effector cell therapy (including
CAR-T/CAR-NK), and regenerative therapeutics. For more information
about Avalon GloboCare, please visit www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024